Umbilical cord

Generate Life Sciences' Cord Blood Registry (CBR®) Enrolls 200,000 Families in its Family Health Registry

Retrieved on:

Tuesday, September 14, 2021

LOS ANGELES, Sept. 14, 2021 /PRNewswire/ --Today, Generate Life Sciences announced a new milestone by enrolling 200,000 families in its Family Health Registry.

Key Points:

LOS ANGELES, Sept. 14, 2021 /PRNewswire/ --Today, Generate Life Sciences announced a new milestone by enrolling 200,000 families in its Family Health Registry.
"The Family Health Registry was created to make it easy for families to connect with relevant stem cell trials.
Newborn stem cells encompass all stem cell types derived from the umbilical cord, including hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue.
Another distinguishing aspect of the Family Health Registry is data collection over long periods of time.

Americord Promotes Client Bill of Rights During Cord Blood Awareness Month

Retrieved on:

Thursday, July 1, 2021

General Health, Hospitals, Consumer, Health, Baby, Maternity, Branches of biology, Stem cells, Biology, Anatomy, Blood, Childbirth, Cord blood, Placenta, Cord blood bank, Umbilical cord

As part of Cord Blood Awareness Month, Americord Registry reminds expecting parents of the Americord Client Bill of Rights.

Key Points:

As part of Cord Blood Awareness Month, Americord Registry reminds expecting parents of the Americord Client Bill of Rights.
The Client Bill of Rights informs and clarifies the outcomes and benefits from banking a childs cord blood, cord tissue, and placental tissue.
We believe Cord Blood Awareness Month is a fitting time to remind expecting parents of our Client Bill of Rights, said Martin Smithmyer, Founder and CEO.
Cord Blood Awareness Month is an important reminder for families to research their options.

Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results

Retrieved on:

Tuesday, June 22, 2021

Branches of biology, Stem cells, Biology, Life sciences, Cord blood bank, Cord blood, Umbilical cord, Hematopoietic stem cell, Cordlife, LifeCell International

HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the fourth quarterand full year fiscal 2021 on Monday, June 28, 2021, after the U.S. market close.

Key Points:

HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the fourth quarterand full year fiscal 2021 on Monday, June 28, 2021, after the U.S. market close.
ET on Tuesday, June 29, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session.
Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

StemCyte Inc. Extends Umbilical Cord Blood Collection Operation at Three Hospital Collection Sites in Southern California

Retrieved on:

Wednesday, May 12, 2021

Branches of biology, Stem cells, Biology, Blood, Childbirth, Embryology, Cord blood bank, Sibling, Cord blood, Umbilical cord, Umbilical, Relicord

As these sites employ a hybrid collector-physician model, physicians and midwives will continue to collect cord blood afterhours.

Key Points:

As these sites employ a hybrid collector-physician model, physicians and midwives will continue to collect cord blood afterhours.
This added coverage to each site allows StemCyte to be able to offer more patients the opportunity to participate in California\'s Umbilical Cord Blood Collection Program.\nThis Umbilical Cord Blood Collection Program (UCBCP) is aCalifornia statewide program administered by UC Davis Health.
"It is a great honor and privilege for StemCyte to be partnered with UC Davis for California\'s Umbilical Cord Blood Program (UCBCP).
The collection service is the state\'s first comprehensive public system for collecting cord blood that will be stored at an established, qualified cord blood bank like StemCyte.

University of Houston Student Yusuf Khan Receives Recognition from Texas Governor Abbott for His Efforts to Increase Awareness of the National Marrow Donor Program/Be The Match

Retrieved on:

Tuesday, April 27, 2021

Branches of biology, Stem cells, Medical specialties, Biology, Childbirth, National Marrow Donor Program, Blood, Umbilical cord, Cord blood, Organ transplantation, Gift of Life Marrow Registry, Hematopoietic stem cell transplantation

b'AUSTIN, Texas, April 27, 2021 /PRNewswire/ --National Marrow Donor Program (NMDP)/Be The Match is honoring a University of Houston student, Yusuf Khan, during Be The Match Day at the Capitol on Tuesday, April 27.

Key Points:

b'AUSTIN, Texas, April 27, 2021 /PRNewswire/ --National Marrow Donor Program (NMDP)/Be The Match is honoring a University of Houston student, Yusuf Khan, during Be The Match Day at the Capitol on Tuesday, April 27.
HB 780 will undoubtedly help improve the likelihood of patients battling leukemia and other blood diseases to find matching donors.
"\nDespite the large number of individuals on the registry, more than 10,000 patients each year will not find a matching donor.
Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant.

BD Commits $1M To Fight Maternal And Neonatal Tetanus

Retrieved on:

Tuesday, April 20, 2021

Branches of biology, Tetanus, Neonatal tetanus, Neonatology, Childhood, Biology, Infant, U.S. Fund for UNICEF, BD, Umbilical cord

The cash donation will be used to support UNICEF\'s efforts to eliminate Maternal and Neonatal Tetanus (MNT) in at-risk countries around the world.

Key Points:

The cash donation will be used to support UNICEF\'s efforts to eliminate Maternal and Neonatal Tetanus (MNT) in at-risk countries around the world.
In 1997, BD was the first U.S.-based corporation to establish a maternal and newborn tetanus program with UNICEF.\nWith the support of BD, UNICEF is working to eliminate maternal and neonatal tetanus worldwide by seeking to vaccinate all women and girls of childbearing age, by promoting clean childbirth delivery practices such as clean umbilical cord cutting methods and by utilizing surveillance to enhance health professionals\' understanding of the circumstances under which tetanus can be transmitted.
"\n"UNICEF won\'t stop working until maternal and neonatal tetanus is eliminated," said Michael J. Nyenhuis, UNICEF USA President and CEO.
For more information on BD, pleasevisit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .\n'

Be The Match Shares Support For Texas Statewide Bone Marrow Recruitment Program

Retrieved on:

Wednesday, March 31, 2021

Branches of biology, Stem cells, Medical specialties, Biology, Childbirth, National Marrow Donor Program, Blood, Cord blood, Umbilical cord, Organ transplantation, Gift of Life Marrow Registry, Center for International Blood and Marrow Transplant Research

MINNEAPOLIS, March 31, 2021 /PRNewswire/ --National Marrow Donor Program/Be The Match, today announced its strong support of Texas Automobile License for Life (TALL Act HB780).

Key Points:

MINNEAPOLIS, March 31, 2021 /PRNewswire/ --National Marrow Donor Program/Be The Match, today announced its strong support of Texas Automobile License for Life (TALL Act HB780).
National Marrow Donor Program (NMDP)/Be The Match is entrusted by Congress to operate the C.W.
Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant.
Be The Match provides patients and their families one-on-one support, education, and guidance before, during and after transplant.

OrganaBio Launches Its HematoPAC™ Cord Blood-Derived CD34+ Hematopoietic Stem Cells (HSCs)

Retrieved on:

Thursday, March 11, 2021

Science, Stem cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Other Health, Branches of biology, Biology, Stem cells, Life sciences, Hematopoietic stem cell, CD34, Cord blood, Umbilical cord, Techniques to isolate haematopoietic stem cells, Haematopoietic system

OrganaBio, LLC (OrganaBio) announces the launch of the HematoPAC-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic cell therapies.

Key Points:

OrganaBio, LLC (OrganaBio) announces the launch of the HematoPAC-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic cell therapies.
View the full release here: https://www.businesswire.com/news/home/20210311005075/en/
OrganaBio's HematoPAC-HSC-CB CD34+ hematopoietic stem cells (HSCs) are isolated from fresh cord blood, within hours of birth.
(Photo: OrganaBio, LLC)
HematoPAC-HSC-CB cells are derived from full-term umbilical cord blood obtained from consented, non-compensated donors under IRB approved protocols.
Umbilical cord blood is a rich source of CD34+ HSCs for HSC transplantation and other HSC-based cell therapies.

Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2021 Financial Results

Retrieved on:

Friday, February 19, 2021

Branches of biology, Stem cells, Biology, Life sciences, Cord blood bank, Cord blood, Umbilical cord, Hematopoietic stem cell, Cordlife, LifeCell International

HONG KONG, Feb. 19, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the thirdquarter and first nine months of fiscal year 2021 on Wednesday, February 24, 2021, after the U.S. market close.

Key Points:

HONG KONG, Feb. 19, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the thirdquarter and first nine months of fiscal year 2021 on Wednesday, February 24, 2021, after the U.S. market close.
ET on Thursday, February 25, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session.
Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

Global Cord Blood Banking Industry Report 2021: Industry Trends, Expansion Technologies, Profiles of Select Cord Blood Banks and Companies

Retrieved on:

Wednesday, January 13, 2021

Branches of biology, Stem cells, Blood, Biology, Medical specialties, Childbirth, Cord blood bank, Sibling, Cord blood, Cordlife, Umbilical cord

DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Global Cord Blood Banking Industry Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Global Cord Blood Banking Industry Report 2021" report has been added to ResearchAndMarkets.com's offering.
From the early 1900s through the mid-2000s, the global cord blood banking industry proliferated with cord blood banks emerging in all major healthcare markets worldwide.
Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation.
What are the prices for processing and storage of cord blood in private cord blood banks?